A new catalytic method has been investigated to obtain either O-or C-allylated phenolic products using allyl alcohol or diallyl ether as the allyl donor. With the use of new cationic rutheni-A C H T U N G T R E N N U N G um(II) complexes as catalyst, both reactions can be performed with good selectivity. Active cationic Ru(II) complexes, having cyclopentadienyl and bidentate phosphine ligands are generated from the corresponding Ru(II) chloride complexes with a silver salt. The structures of three novel (diphos-A C H T U N G T R E N N U N G phine)Ru(II)CpCl catalyst precursor complexes are reported. It appears that the structure of the bidentate ligand has a major influence on catalytic activity as well as chemoselectivity. In addition, a strong cocatalytic effect of small amounts of acid is revealed. Model experiments are described that have been used to build a reaction network that explains the origin and evolution in time of both O-allylated and C-allylated phenolic products. Some mechanistic implications of the observed structure vs. performance relation of the [(diphosphine)RuCp] + complexes and the cocatalytic role of added protons are discussed.
The catalytic performance of a series of novel cationic ruthenium(II) complexes with cyclopentadienyl and bidentate phosphine ligands was explored to establish a catalyst structure−performance relationship and gain mechanistic insight in the selective O-allylation of a phenol with allyl alcohol. It appears that catalysts containing bidentate phosphine ligands having geminal dialkyl substituents at the central atom of a C3-bridging group of the phosphine ligand are highly selective for O-allylation; apparently the presence of the substituents efficiently blocks the competitive and thermodynamically more favorable pathway to C-allylation. It appears that the electronic and structural properties of the Ru(II) precursor complexes in the solid state do not differ significantly from those of complexes containing unsubstituted analogous ligands, while the resulting catalysts show a vastly different catalytic performance. The complex [RuCp(dppp)](OTs), with the unsubstituted ligand, after six hours yields 70% conversion of phenol with a selectivity for O-allylation of only 27%, whereas the complex [RuCp(dppdmp)](OTs), with the dimethyl-substituted ligand, after six hours gives 60% conversion of phenol with 82% selectivity for O-allylation. The results suggest that the geminal dialkyl substitution at the central carbon of the C3 bridge of the ligand primarily leads to an increased kinetic stability of the bidentate chelate under reaction conditions, such as in the proposed intermediate [Ru(IV)(Cp)(diphosphine)(allyl)]2+ complexes. This implies that the high kinetic stability of the diphosphine chelate bound to Ru blocks the pathway to the thermodynamically favored C-allylation product. The results provide an interesting example in which the application of the geminal dialkyl substitution in the bridge of a bidentate ligand serves as a diagnostic tool to probe the nature of the selectivity-determining step in a catalytic pathway in homogeneous catalysis.
Tris(o-anisyl)phosphane was reacted with ruthenium(III) chloride forming a novel Ru(III) complex of formula [Ru(PAn(3))(P(An)(phenolate)(2))Cl] containing a tridentate dianionic P,O,O-ligand and a bidentate neutral P,O ligand. The tridentate ligand was formed by elimination of two methyl groups from the starting ligand in the reaction with the ruthenium salt. The molecular structure was determined by single crystal X-ray diffraction analysis. The compound shows a high cytotoxic activity in ovarian cancer cell lines comparable with cisplatin and overcoming cisplatin-resistance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.